Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Raw Materials: 2019-2025

  • China SXT Pharmaceuticals' Raw Materials rose 35.88% to $435,799 in Q1 2025 from the same period last year, while for Mar 2025 it was $435,799, marking a year-over-year increase of 35.88%. This contributed to the annual value of $435,799 for FY2025, which is 35.88% up from last year.
  • China SXT Pharmaceuticals' Raw Materials amounted to $435,799 in Q1 2025, which was up 35.88% from $320,722 recorded in Q1 2024.
  • In the past 5 years, China SXT Pharmaceuticals' Raw Materials registered a high of $435,799 during Q1 2025, and its lowest value of $243,222 during Q1 2023.
  • Its 3-year average for Raw Materials is $333,248, with a median of $320,722 in 2024.
  • Data for China SXT Pharmaceuticals' Raw Materials shows a peak YoY surged of 35.88% (in 2025) over the last 5 years.
  • Over the past 3 years, China SXT Pharmaceuticals' Raw Materials (Quarterly) stood at $243,222 in 2023, then spiked by 31.86% to $320,722 in 2024, then surged by 35.88% to $435,799 in 2025.
  • Its last three reported values are $435,799 in Q1 2025, $320,722 for Q1 2024, and $243,222 during Q1 2023.